Episode Details:
Our Guest: Sharon Rogers, CEO at AmyriAD Therapeutics
What you’ll get out of this episode:
- Rogers’ background
- An overview of AmyriAD Therapeutics
- The company’s lead compound, AD101
- Their clinical trials & what they’re showing
- Launching a Phase 3 Study
- What’s next?
Watch and listen here: #345 – Sharon Rogers, CEO at AmyriAD Therapeutics – Slice of Healthcare